Johnson & Johnson SEC Filings

Johnson & Johnson executive Kristen Mulholland, EVP and Chief HR Officer, acquired 3,602 Performance Share Units (PSUs) on February 9, 2026. These PSUs were originally granted on February 13, 2023 under the company’s Long-Term Incentive Plan and convert into shares of common stock upon vesting.

The 3,602 PSUs reflect the target award adjusted based on certified achievement of the performance conditions in the award agreement as of February 9, 2026. Following this transaction, Mulholland directly holds 3,602 derivative securities tied to Johnson & Johnson common stock.

Johnson & Johnson reported that EVP and Chief Legal Officer Elizabeth Forminard acquired 13,706 Performance Share Units (PSUs) on February 9, 2026 as a grant under the company’s long-term incentive plan.

The PSUs, originally granted on February 13, 2023, convert into an equal number of Johnson & Johnson common shares upon vesting, with the final number certified based on achievement of performance conditions as of February 9, 2026.

Johnson & Johnson CEO and Chairman Joaquin Duato reported receiving an equity award tied to company performance. On February 9, 2026, he acquired 73,054 Performance Share Units (PSUs) at a price of $0 per unit. These PSUs were originally granted on February 13, 2023 under the long-term incentive plan and convert into an equal number of Johnson & Johnson common shares upon vesting, based on performance conditions that were certified on February 9, 2026.

Johnson & Johnson executive equity award: Vice President and Corporate Controller Robert J. Decker acquired 2,741 Performance Share Units (PSUs) on February 9, 2026 as a grant under the company’s long-term incentive plan. These PSUs were originally granted on February 13, 2023 and convert into shares of common stock upon vesting, with the final number reflecting certified achievement of performance conditions.

Johnson & Johnson executive Kathryn E. Wengel reported an equity award tied to company performance. On February 9, 2026, she acquired 13,706 Performance Share Units at a price of $0 under Johnson & Johnson’s long-term incentive plan.

The PSUs were originally granted on February 13, 2023 and convert into shares of common stock when they vest. The 13,706 units represent the target grant amount adjusted based on achievement of the performance conditions specified in the award agreement, as certified on February 9, 2026. Following this transaction, she directly holds 13,706 derivative securities in the form of PSUs.

Johnson & Johnson executive Vanessa Broadhurst, EVP, Global Corporate Affairs, reported an equity compensation transaction. On February 9, 2026, she acquired 8,594 Performance Share Units (PSUs) at a price of $0 per unit under the company’s long-term incentive plan.

The PSUs were originally granted on February 13, 2023 and convert into shares of Johnson & Johnson common stock upon vesting. The reported 8,594-unit figure reflects the target PSUs adjusted based on achievement of performance conditions, which were certified on February 9, 2026. Following this transaction, she directly holds 8,594 derivative securities linked to common stock.

Johnson & Johnson has filed a shelf registration that allows it to offer debt securities from time to time after the registration becomes effective. The specific terms of each series, including interest structure and maturity, will be set in separate prospectus supplements.

The debt securities will be unsecured obligations issued under an existing indenture and may be sold directly or through agents, dealers, or underwriters. Unless a prospectus supplement states otherwise, net proceeds will be used for general corporate purposes such as working capital, capital expenditures, stock repurchase programs, refinancing of borrowings and acquisitions.

Johnson & Johnson files its annual report describing a diversified healthcare business built around two segments: Innovative Medicine and MedTech. Innovative Medicine spans oncology, immunology, neuroscience, infectious disease and cardiovascular care, with flagship drugs like DARZALEX, STELARA and TREMFYA contributing a significant share of revenue.

MedTech covers cardiovascular, orthopaedics, surgery and vision products, including electrophysiology tools, Shockwave and Abiomed technologies, surgical stapling and Acuvue contact lenses. The company plans to separate its Orthopaedics business within 18 to 24 months after an October 2025 announcement, adding execution and structural risk.

The report details extensive risk factors, including loss of patent exclusivity, biosimilar competition, global pricing pressure, U.S. Inflation Reduction Act drug price controls, complex regulation, large-scale litigation exposure, cybersecurity and data-privacy threats, global supply-chain vulnerabilities and geopolitical instability. J&J employs about 140,800 people worldwide and emphasizes human capital, culture, compliance and cybersecurity governance.

Johnson & Johnson executive Timothy Schmid, EVP and Worldwide Chair of MedTech, reported routine equity transactions on February 6, 2026. He exercised 15,571 employee stock options at $101.87 per share through an automatic exercise immediately before expiration, receiving the same number of common shares.

To cover the option exercise price and related taxes, 10,335 common shares were withheld at a value of $239.99 per share, leaving 22,125 common shares held directly after the transactions. He also reports indirect ownership of 745 shares through a 401(k) plan and 46 shares through an ESOP under the Johnson & Johnson Savings Plan.